Bioactivation of selective estrogen receptor modulators (SERMs)

Chemical Research in Toxicology

Volumn 19, Issue 9, 2006, Pages 1125-1137

  Dowers, Tamara S ^a   Qin, Zhi Hui ^a   Thatcher, Gregory R J ^a   Bolton, Judy L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 QUINONE; 3,4 DIHYDROXYTAMOXIFEN; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; 4 FLUORONORARZOXIFENE; 4 HYDROXYEQUILENIN; ACOLBIFENE; ARZOXIFENE; BENZOPYRAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; CARBOCATION; CARBON; CARCINOGEN; CATION; CYTOCHROME P450 2C9; DROLOXIFENE; DRUG METABOLITE; EQUILENIN; ESTROGEN RECEPTOR; FULVESTRANT; IDOXIFENE; LSN 2120310; LUCIFERASE; LY 2066948; NORARZOXIFENE; QUINONE DERIVATIVE; QUINONE METHIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CORONARY ARTERY DISEASE; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; OUTCOMES RESEARCH; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTMENOPAUSE OSTEOPOROSIS; REACTION ANALYSIS; REVIEW; TOXICITY TESTING; TRANSCRIPTION REGULATION; UTERUS CANCER; WESTERN BLOTTING;

ANIMALS; BIOTRANSFORMATION; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33748994836     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx060126v     Document Type: Review

References (143)

1. Smigel, K. (1998) Breast Cancer Prevention Trial shows major benefit, some risk. J. Natl. Cancer Inst. 90, 647-648.
2. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388.
3. Jordan, V. C., and Morrow, M. (1999) Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev. 20, 253-278.
4. Henderson, B. E., Ross, R., and Bernstein, L. (1988) Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 48, 246-253.
5. Friedl, A., and Jordan, V. C. (1994) What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res. Treat. 31, 27-39.
6. Cohen, I., Rosen, D. J., Shapira, J., Cordoba, M., Gilboa, S., Altaras, M. M., Yigael, D., and Beyth, Y. (1994) Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol. Oncol. 52, 185-190.
7. Roy, R. N., Gerulath, A. H., Cecutti, A., and Bhavnani, B. R. (2000) Effect of tamoxifen treatment on the endometrial expression of human insulin-like growth factors and their receptor mRNAs. Mol. Cell. Endocrinol. 165, 173-178.
8. Shibutani, S., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12, 646-653.
9. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461-1467.
10. Zhang, F., Fan, P. W., Liu, X., Shen, L., van Breeman, R. B., and Bolton, J. L. (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-Dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol. 13, 53-62.
11. Fan, P. W., Zhang, F., and Bolton, J. L. (2000) 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremitene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 13, 45-52.
12. Bolton, J. L. (2002) Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 177, 55-65.
13. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160.
14. Kim, S. Y., Suzuki, N., Laxmi, Y. R., and Shibutani, S. (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 36, 199-218.
15. Katzenellenbogen, B. S., Montano, M. M., Ediger, T. R., Sun, J., Ekena, K., Lazennec, G., Martini, P. G., McInerney, E. M., Delage-Mourroux, R., Weis, K., and Katzenellenbogen, J. A. (2000) Estrogen receptors: Selective ligands, partners, and distinctive pharmacology. Recent Prog. Horm. Res. 55, 163-193; discussion 194-165.
16. Katzenellenbogen, B. S., Sun, J., Harrington, W. R., Kraichely, D. M., Ganessunker, D., and Katzenellenbogen, J. A. (2001) Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann. N. Y. Acad. Sci. 949, 6-15.
17. McKenna, N. J., and O'Malley, B. W. (2000) An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nat. Med. 6, 960-962.
18. Rhodes, D. J., Hartmann, L. C., and Perez, E. A. (2000) Breast cancer prevention trials. Curr. Oncol. Rep. 2, 558-565,
19. Phillips, C. (2006) STAR results: Raloxifene as effective as tamoxifen, better safety profile. NCI Cancer Bulletin 3, 1-2.
20. McDonnell, D. P., and Morris, J. D. (2002) Connections and regulation of the human estrogen receptor. Science 296, 1642-1644,
21. McKenna, N. J., Lanz, R. B., and O'Malley, B. W. (1999) Nuclear receptor coregulators: Cellular and molecular biology. Endocr. Rev. 20, 321-344.
22. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and Webb, P. (2000) Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317.
23. Kushner, P. J., Agard, D., Feng, W. J., Lopez, G., Schiau, A., Uht, R., Webb, P., and Greene, G. (2000) Oestrogen receptor function at classical and alternative response elements. Novartis Found. Symp. 230, 20-26; discussion 27-40.
24. Watanabe, T., Inoue, S., Hiroi, H., Orimo, A., Kawashima, H., and Muramatsu, M. (1998) Isolation of estrogen-responsive genes with a CpG island library. Mol. Cell. Biol. 18, 442-449.
25. Dubik, D., and Shiu, R. P. (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7, 1587-1594.
26. Umayahara, Y., Kawamori, R., Watada, H., Imano, E., Iwama, N., Morishima, T., Yamasaki, Y., Kajimoto, Y., and Kamada, T. (1994) Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. 269, 16433-16442.
27. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852.
28. Smith, C. L., and O'Malley, B. W. (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71.
29. Shang, Y., and Brown, M. (2002) Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468.
30. Tsai, M. J., and O'Malley, B. W. (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451-486.
31. Beato, M., Herrlich, P., and Schutz, G. (1995) Steroid hormone receptors: Many actors in search of a plot. Cell 83, 851-857.
32. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., and Gustafsson, J. A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863-870.
33. Korach, K. S. (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266, 1524-1527.
34. Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., and Korach, K. S. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331, 1056-1061.
35. Gradishar, W. J., and Jordan, V. C. (1997) Clinical potential of new antiestrogens. J. Clin. Oncol. 15, 840-852.
36. Jordan, V. C. (1998) Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow. J. Natl. Cancer Inst. 90, 967-971.
37. Manas, E. S., Unwalla, R. J., Xu, Z. B., Malamas, M. S., Miller, C. P., Harris, H. A., Hsiao, C., Akopian, T., Hum, W. T., Malakian, K., Wolfrom, S., Bapat, A., Bhat, R. A., Stahl, M. L., Somers, W. S., and Alvarez, J. C. (2004) Structure-based design of estrogen receptor-beta selective ligands. J. Am. Chem. Soc. 126, 15106-15119.
38. Hillisch, A., Peters, O., Kosemund, D., Muller, G., Walter, A., Schneider, B., Reddersen, G., Elger, W., and Fritzemeier, K. H. (2004) Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol. Endocrinol. 18, 1599-1609.
39. Gungor, T., Chen, Y., Golla, R., Ma, Z., Corte, J. R., Northrop, J. P., Bin, B., Dickson, J. K., Stouch, T., Zhou, R., Johnson, S. E., Seethala, R., and Feyen, J. H. (2006) Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J. Med. Chem. 49, 2440-2455.
40. Harris, H. A., Albert, L. M., Leathurby, Y., Malamas, M. S., Mewshaw, R. E., Miller, C. P., Kharode, Y. P., Marzolf, J., Komm, B. S., Winneker, R. C., Frail, D. E., Henderson, R. A., Zhu, Y., and Keith, J. C., Jr. (2003) Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144, 4241-4249.
41. Shang, Y. (2006) Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer 6, 360-368.
42. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937.
43. Grese, T. A., Sluka, J. P., Bryant, H. U., Cullinan, G. J., Glasebrook, A. L., Jones, C. D., Matsumoto, K., Palkowitz, A. D., Sato, M., Termine, J. D., Winter, M. A., Yang, N. N., and Dodge, J. A. (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. U.S.A. 94, 14105-14110.
44. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and Chambon, P. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494.
45. Kumar, V., Green, S., Stack, G., Berry, M., Jin, J. R., and Chambon, P. (1987) Functional domains of the human estrogen receptor. Cell 51, 941-951.
46. Moras, D., and Gronemeyer, H. (1998) The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10, 384-391.
47. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758.
48. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., and Tung, L. (1996) Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10, 1167-1177.
49. Glass, C. K., Rose, D. W., and Rosenfeld, M. G. (1997) Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9, 222-232.
50. Feng, W., Ribeiro, R. C., Wagner, R. L., Nguyen, H., Apriletti, J. W., Fletterick, R. J., Baxter, J. D., Kushner, P. J., and West, B. L. (1998) Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280, 1747-1749.
51. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736.
52. Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and Rosenfeld, M. G. (1997) The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387, 677-684.
53. Ding, X. F., Anderson, C. M., Ma, H., Hong, H., Uht, R. M., Kushner, P. J., and Stallcup, M. R. (1998) Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities. Mol. Endocrinol. 12, 302-313.
54. Le Douarin, B., Nielsen, A. L., Garnier, J. M., Ichinose, H., Jeanmougin, F., Losson, R., and Chambon, P. (1996) A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 15, 6701-6715.
55. Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2002) Biomedicine. Defining the "S" in SERMs. Science 295, 2380-2381.
56. Beland, F. A., Marques, M. M., Gamboa da Costa, G., and Phillips, D. H. (2005) Tamoxifen-DNA adduct formation in human endometrium. Chem. Res. Toxicol. 18, 1507-1509; author reply 1509-1511.
57. Carmichael, P. L., Sardar, S., Crooks, N., Neven, P., Van Hoof, I., Ugwumadu, A., Bourne, T., Tomas, E., Hellberg, P., Hewer, A. J., and Phillips, D. H. (1999) Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20, 339-342.
58. Beland, F. A., Churchwell, M. I., Hewer, A., Phillips, D. H., da Costa, G. G., and Marques, M. M. (2004) Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling. Biochem. Biophys. Res. Commun. 320, 297-302.
59. Liu, J., Liu, H., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2005) Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem. Res. Toxicol. 18, 174-182.
60. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2004) Oxidation of raloxifene to quinoids: Potential toxic pathways via a diquinone methide and o-quinones. Chem. Res. Toxicol. 17, 879-888.
61. Liu, H., Liu, J., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2005) Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-Fluoro substitution prevents quinoid formation. Chem. Res. Toxicol. 18, 162-173.
62. Liu, J., Li, Q., Yang, X., van Breemen, R. B., Bolton, J. L., and Thatcher, G. R. (2005) Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: Raloxifene proof-of-principle study. Chem. Res. Toxicol. 18, 1485-1496.
63. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
64. Dehal, S. S., and Kupfer, D. (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechoh Involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 27, 681-688.
65. Dehal, S. S., and Kupfer, D. (1996) Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56, 1283-1290.
66. Fisher, B., and Redmond, C. (1991) New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst. 83, 1278-1280.
67. Killackey, M. A., Hakes, T. B., and Pierce, V. K. (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 69, 237-238.
68. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Silfversward, C., Skoog, L., Somell, A., Theve, T., Wilking, N., and et al. (1989) Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1, 117-120.
69. Cohen, C. J., and Rahaman, J. (1995) Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy. Cancer 76, 2044-2052.
70. Nease, R. F., Jr., and Ross, J. M. (1995) The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs. Am. J. Med. 99, 180-189.
71. King, C. M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis 16, 1449-1454.
72. Vancutsem, P. M., Lazarus, P., and Williams, G. M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res. 54, 3864-3867.
73. Fendel, K. C. Z. S. J. (1992) Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res. 235-237.
74. Roos, W., Oeze, L., Loser, R., and Eppenberger, U. (1983) Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. J. Natl. Cancer Inst. 71, 55-59.
75. White, I. N., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
76. Pace, P., Jarman, M., Phillips, D., Hewer, A., Bliss, J., and Coombes, R. C. (1997) Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br. J. Cancer 76, 700-704.
77. Johnston, S. R., Riddler, S., Haynes, B. P., A'Hern, R., Smith, I. E., Jarman, M., and Dowsett, M. (1997) The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br. J. Cancer 75, 804-809.
78. White, I. N., Martin, E. A., Mauthe, R. J., Vogel, J. S., Turteltaub, K. W., and Smith, L. L. (1997) Comparisons of the binding of [14C]-radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem.-Biol. Interact. 106, 149-160.
79. Kim, S. Y., Suzuki, N., Laxmi, Y. R., and Shibutani, S. (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 36, 199-218.
80. Johnston, S. R. (2001). Endocrine manipulation in advanced breast cancer: Recent advances with SERM therapies. Clin. Cancer Res. 7, 4376s-4387s; discussion 4411s-4412s.
81. Gradishar, W., Glusman, J., Lu, Y., Vogel, C., Cohen, F. J., and Sledge, G. W., Jr. (2000) Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88, 2047-2053.
82. Eli Lilly and Company (Issued April 12, 2006). Lilly announces preliminary coronary and breast cancer. Results from Raloxifene Use for The Heart (RUTH) study. Available online at http://newsroom.lilly.com/ReleaseDetail. cfm?ReleaseID=192692.
83. Dardes, R. C., Bentrem, D., O'Regan, R. M., Schafer, J. M., and Jordan, V. C. (2001) Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. Clin. Cancer Res. 7, 4149-4155.
84. McMeekin, D. S., Gordon, A., Fowler, J., Melemed, A., Buller, R., Burke, T., Bloss, J., and Sabbatini, P. (2003) A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol. Oncol. 90, 64-69.
85. Baselga, J., Llombart-Cussac, A., Bellet, M., Guillem-Porta, V., Enas, N., Krejcy, K., Carrasco, E., Kayitalire, L., Kuta, M., Lluch, A., Vodvarka, P., Kerbrat, P., Namer, M., and Petruzelka, L. (2003) Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann. Oncol. 14, 1383-1390.
86. Chan, S. (2002) Arzoxifene in breast cancer. Eur. J. Cancer. 38 (Suppl. 6), S55-S56.
87. Vernon, M. W. (1990) Experimental endometriosis in laboratory animals as a research model. Prog. Clin. Biol. Res. 323, 49-60.
88. Thomas, W., Burke, M. D., and Walker, C. L. (2003) Arzoxifene as therapy for endometrial cancer. Gynecol. Oncol. 90, S40-S46.
89. Munster, P. N. (2006) Arzoxifene: The development and clinical outcome of an ideal SERM. Exp. Opin. Invest. Drugs 15, 317-326.
90. Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C., Peer, C., Wang, Y., and Sporn, M. B. (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61, 8412-8415.
91. Gauthier, S., Caron, B., Cloutier, J., Dory, Y. L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Merand, Y., Belanger, A., Labrie, C., and Labrie, F. (1997)(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl 2,2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active nonsteroidal antiestrogen. J. Med. Chem. 40, 2117-2122.
92. Simard, J., Labrie, C., Belanger, A., Gauthier, S., Singh, S. M., Merand, Y., and Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer 73, 104-112.
93. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S. M., Merand, Y., Belanger, A., Labrie, C., and Labrie, F. (1997) Blockade of the stimulatory effect of estrogens. OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 57, 3494-3497.
94. Couillard, S., Gutman, M., Labrie, C., Belanger, A., Candas, B., and Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res. 58, 60-64.
95. Luo, S., Labrie, C., Belanger, A., and Labrie, F. (1997). Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a) anthracene-induced mammary carcinoma in the rat. Endocrinology 138, 3387-3394.
96. Jordan, V. C. (2004) Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 5, 207-213.
97. Sharma, M., Shubert, D. E., Lewis, J., McGarrigle, B. P., Bofinger, D. P., and Olson, J. R. (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem.-Biol. Interact. 146, 237-249.
98. Kim, S. Y., Laxmi, Y. R., Suzuki, N., Ogura, K., Watabe, T., Duffel, M. W., and Shibutani, S. (2005) Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation of alpha-hydroxytamoxifen in rat and human livers. Drug Metab. Dispos. 33, 1673-1678.
99. Kim, S. Y., Suzuki, N., Laxmi, Y. R., McGarrigle, B. P., Olson, J. R., Sharma, M., and Shibutani, S. (2005) Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen. Chem. Rex. Toxicol. 18, 889-895.
100. Brown, K., and Carmichael, P. L. (2003) Correspondence regarding M. Sharma et al., Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. Biochem. Biophys. Res. Commun. 310, 1039.
101. Poon, G. K., Walter, B., Lonning, P. E., Horton, M. N., and McCague, R. (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23, 377-382.
102. Sharma, M., Shubert, D. E., Rodabaugh, K. J., McGarrigle, B. P., Vezina, C. M., Bofinger, D. P., and Olson, J. R. (2003) Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. Biochem. Biophys. Res. Commun. 307, 157-164.
103. Kim, S. Y., Suzuki, N., Santosh Laxmi, Y. R., Rieger, R., and Shibutani, S. (2003) α-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol. 16, 1138-1144.
104. Shibutani, S., Ravindernath, A., Terashima, I., Suzuki, N., Laxmi, Y. R., Kanno, Y., Suzuki, M., Apak, T. I., Sheng, J. J., and Duffel, M. W. (2001) Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res. 61, 3925-3931.
105. Kuramochi, H. (1996) Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J. Med. Chem. 39, 2877-2886.
106. Thompson, D. C., Thompson, J. A., Sugumaran, M., and Moldeus, P. (1993) Biological and toxicological consequences of quinone methide formation. Chem.-Biol. Interact. 86, 129-162.
107. Thompson, D. C., Perera, K., Krol, E. S., and Bolton, J. L. (1995) o-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Chem. Res. Toxicol. 8, 323-327.
108. Peter, M. G. (1989) Chemical modifications of bio-polymers by quinones and quinone methides. Angew. Chem. Int. Ed. 28, 555-570.
109. Monks, T. J., Hanzlik, R. P., Cohen, G. M., Ross, D., and Graham, D. G. (1992) Quinone chemistry and toxicity. Toxicol. Appl. Pharmacol. 112, 2-16.
110. Richard, J. P., Amyes, T. L., Bei, L., and Stubblefield, V. (1990) The effect of β-fluorine substituents on the rate and equilibrium-constants for the reactions of α-substituted 4-methoxybenzyl carbocations and on the reactivity of a simple quinone methide. J. Am. Chem. Soc. 112, 9513-9519.
111. Hulbert, P. B., and Grover, P. L. (1983) Chemical rearrangement of phenol-epoxide metabolites of polycyclic aromatic hydrocarbons to quinone-methides. Biochem. Biophys. Res. Commun. 117, 129-134.
112. Potter, G. A., McCague, R., and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 15, 439-442.
113. Bolton, J. L., Comeau, E., and Vukomanovic, V. (1995) The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxyquinone methides: Evidence that extended pi-conjugation dramatically stabilizes the quinone methide formed from eugenol. Chem.-Biol. Interact. 95, 279-290.
114. Dehal, S. S., and Kupfer, D. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57, 3402-3406.
115. Crewe, H. K., Ellis, S. W., Lennard, M. S., and Tucker, G. T. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171-178.
116. Wiseman, H., and Lewis, D. F. (1996) The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: Potential importance to its proposed anti-carcinogenic/ carcinogenic actions. Carcinogenesis 17, 1357-1360.
117. Kroemer, H. K., and Eichelbaum, M. (1995) "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56, 2285-2298.
118. Wilkinson, G. R., Guengerich, F. P., and Branch, R. A. (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43, 53-76.
119. Coezy, E., Borgna, J. L., and Rochefort, H. (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42, 317-323.
120. Borgna, J. L., and Rochefort, H. (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256, 859-868.
121. Hochner-Celnikier, D. (1999) Pharmacokinetics of raloxifene and its clinical application. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 23-29.
122. Snyder, K. R., Sparano, N., and Malinowski, J. M. (2000). Raloxifene hydrochloride. Am. J. Health Syst. Pharm. 57, 1669-675; quiz 1676-1668.
123. Fiorelli, G., Picariello, L., Martineti, V., Tonelli, F., and Brandi, M. L. (1999) Estrogen synthesis in human colon cancer epithelial cells. J. Steroid Biochem. Mol. Biol. 71, 223-230.
124. Buzdar, A., O'Shaughnessy, J. A., Booser, D. J., Pippen, J. E., Jr., Jones, S. E., Munster, P. N., Peterson, P., Melemed, A. S., Winer, E., and Hudis, C. (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 21, 1007-1014.
125. Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E., and Bryant, H. U. (1998) LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J. Pharmacol. Exp. Ther. 287, 1-7.
126. Kemp, D. C., Fan, P. W., and Stevens, J. C. (2002) Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30, 694-700.
127. Jordan, V. C. (1982) Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance. Breast Cancer Res. Treat. 2, 123-138.
128. Liu, X., Pisha, E., Tonetti, D. A., Yao, D., Li, Y., Yao, J., Burdette, J. E., and Bolton, J. L. (2003) Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem. Res. Toxicol. 16, 832-837.
129. Mani, C., Hodgson, E., and Kupfer, D. (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos. 21, 657-661.
130. Berthou, F., and Dreano, Y. (1993) High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J. Chromatogr. 616, 117-127.
131. Yao, D., Zhang, F., Yu, L., Yang, Y., van Breemen, R. B., and Bolton, J. L. (2001) Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: Droloxifene and toremifene o-quinones. Chem. Res. Toxicol. 14, 1643-1653.
132. Sarabia, S. F., Zhu, B. T., Kurosawa, T., Tohma, M., and Liehr, J. G. (1997) Mechanism of cytochrome P450-catalyzed aromatic hydroxylation of estrogens. Chem. Res. Toxicol. 10, 767-771.
133. Spink, D. C., Zhang, F., Hussain, M. M., Katz, B. H., Liu, X., Hilker, D. R., and Bolton, J. L. (2001) Metabolism of equilenin in MCF-7 and MDA-MB-231 human breast cancer cells. Chem. Res. Toxicol. 14, 572-581.
134. Zhang, F., Chen, Y., Pisha, E., Shen, L., Xiong, Y., van Breemen, R. B., and Bolton, J. L. (1999) The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem. Res. Toxicol. 12, 204-213.
135. Shen, L., Pisha, E., Huang, Z., Pezzuto, J. M., Krol, E., Alam, Z., van Breemen, R. B., and Bolton, J. L. (1997) Bioreductive activation of catechol estrogen-ortho-quinones: Aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity. Carcinogenesis 18, 1093-1101.
136. Chen, Y., Shen, L., Zhang, F., Lau, S. S., van Breemen, R. B., Nikolic, D., and Bolton, J. L. (1998) The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases in vitro. Chem. Res. Toxicol. 11, 1105-1111.
137. Shen, L., Qiu, S., Chen, Y., Zhang, F., van Breemen, R. B., Nikolic, D., and Bolton, J. L. (1998) Alkylation of 2′-deoxynucleosides and DNA by the Premarin metabolite 4-hydroxyequilenin semiquinone radical. Chem. Res. Toxicol. 11, 94-101.
138. Zhang, F., Swanson, S. M., van Breemen, R. B., Liu, X., Yang, Y., Gu, C., and Bolton, J. L. (2001) Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: Formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem. Res. Toxicol. 14, 1654-1659.
139. Yao, J., Chang, M., Li, Y., Pisha, E., Liu, X., Yao, D., Elguindi, E. C., Blond, S. Y., and Bolton, J. L. (2002) Inhibition of cellular enzymes by equine catechol estrogens in human breast cancer cells: Specificity for glutathione S-transferase P1-1. Chem. Res. Toxicol. 15, 935-942.
140. Li, Y., Yao, J., Chang, M., Nikolic, D., Yu, L., Yager, J. D., Mesecar, A. D., van Breemen, R. B., and Bolton, J. L. (2004) Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase. Chem. Res. Toxicol. 17, 512-520.
141. Yao, J., Li, Y., Chang, M., Wu, H., Yang, X., Goodman, J. E., Liu, X., Liu, H., Mesecar, A. D., Van Breemen, R. B., Yager, J. D., and Bolton, J. L. (2003) Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase. Chem. Res. Toxicol. 16, 668-675.
142. Zhang, Z., Chen, Q., Li, Y., Doss, G. A., Dean, B. J., Ngui, J. S., Silva Elipe, M., Kim, S., Wu, J. Y., Dininno, F., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2005) In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: Formation of reactive iminium and quinone type metabolites. Chem. Res. Toxicol. 18, 675-685.
143. Sanchez, C., Shibutani, S., Dasaradhi, L., Bolton, J. L., Fan, P. W., and McClelland, R. A. (1998) Lifetime and reactivity of an ultimate tamoxifen carcinogen: The tamoxifen carbocation. J. Am. Chem. Soc. 120, 13513-13514.